Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

May 14, 2025

Capsida Receives FDA IND Clearance for Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

May 12, 2025

Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)

April 28, 2025

Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson’s Disease Associated with GBA Mutations (PD-GBA)

April 3, 2025

Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration

January 7, 2025

Capsida Biotherapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

December 19, 2024

New Preclinical Data Demonstrate Potential of Capsida’s IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations

December 6, 2024

Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference

November 25, 2024

Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich’s Ataxia Next-Generation Gene Therapy

November 12, 2024

FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy

October 30, 2024

New Data Demonstrate Substantial Therapeutic Potential of Capsida’s IV Gene Therapy for Parkinson’s Disease Associated with GBA Mutations

October 7, 2024

Capsida Biotherapeutics to Participate in Upcoming Investor and Industry Conferences Highlighting Progress With its Wholly Owned Programs in IND-enabling Studies

September 4, 2024

Capsida Biotherapeutics to Present Preclinical Data for Parkinson’s Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration

May 10, 2024

Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations

May 7, 2024

Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson’s Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

April 22, 2024

Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer

March 12, 2024

Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

February 21, 2024

Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies

October 3, 2023

Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa

September 20, 2023

Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy

June 2, 2023

Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting

May 10, 2023

Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer

March 7, 2023

AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need

February 23, 2023

Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer

January 18, 2023

Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases

January 4, 2023

Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

May 18, 2022

Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

May 17, 2022

Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40

April 19, 2022

Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief Operating Officer

March 22, 2022

PharmaVoice profiles Capsida CEO Peter Anastasiou

February 3, 2022

Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver

December 9, 2021

Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO

December 7, 2021

Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference

December 2, 2021

Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing

July 22, 2021

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

June 15, 2021

Capsida Appoints Swati Tole, M.D., as Chief Medical Officer

May 12, 2021

Capsida Biotherapeutics Debuts with $140 Million of Capital

April 29, 2021